From Wikipedia, the free encyclopedia
  (Redirected from MDBZ)
Jump to navigation Jump to search
IUPAC name
  • 65033-29-6 ☑Y
3D model (JSmol)
  • Interactive image
Molar mass 269.343 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
‹See TfM›☒N verify (what is ☑Y‹See TfM›☒N ?)
Infobox references

MDBZ, or 3,4-methylenedioxy-N-benzylamphetamine, is a lesser-known psychedelic drug. It is the N-benzyl derivative of MDA. MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. MDBZ produces few to no effects. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to 3,4-methylenedioxy-N-benzylamphetamine.[1]


United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also


  1. ^ "House of Commons Hansard Written Answers for 23 July 1996 (pt 10)".
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.

External links

  • MDBZ entry in PiHKAL
  • MDBZ entry in PiHKAL • info

Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "Methylenedioxybenzylamphetamine"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA